Connect your AI

Capricor Therapeutics CAPR Earnings yield

Earnings yield at other companies

PfizerPFE

6.8%—

Sarepta Therapeutics, Inc.SRPT

-4%-4.3pp

PTC TherapeuticsPTCT

15.4%+10.2pp

Celldex TherapeuticsCLDX

-13.4%-1.2pp

VericelVCEL

1.3%+1.2pp

Viridian Therapeutics, Inc.VRDN

-18%-4.7pp

Other financials

Income statement

Revenue--100%

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Balance sheet

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Cash flow

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Valuation

Market cap$1.71B+303%

Enterprise value$1.62B+308%

Profitability

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Returns & leverage

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Where this comes from

Calculated from Capricor Therapeutics’s reported figures.

net income/market cap=-6.6%

Based on trailing twelve months.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Capricor Therapeutics's earnings yield?: Capricor Therapeutics (CAPR) reported earnings yield of -6.6% in Q1 2026.
How has Capricor Therapeutics's earnings yield changed year-over-year?: Capricor Therapeutics's earnings yield increased by 48.4% year-over-year, from -12.7% to -6.6%.
What is the long-term trend for Capricor Therapeutics's earnings yield?: Over 5 years (2020 to 2025), Capricor Therapeutics's earnings yield has grown at a -16.5% compound annual growth rate (CAGR), from -16.5% to -6.7%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.